Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Can Good Sleep Prevent Alzheimer's Disease?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 320
Posts 41,861
Boards Moderated 32
Alias Born 09/20/01
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 4/8/2020 4:30:55 PM
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/23/2020 8:01:22 AM
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders GlobeNewswire Inc. - 3/23/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/9/2020 4:28:38 PM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
XenaLives Member Level  Friday, 04/19/19 08:16:19 PM
Re: None
Post # of 245637 
Quote:

Can Good Sleep Prevent Alzheimer's Disease?
Stephanie Rainey-Smith, PhD
Edith Cowan University (Perth, Australia)

MENTORS
Ralph N. Martins, PhD
Edith Cowen University (Perth, Australia)
COLLABORATORS
Melissa Ree, PhD
The Marian Centre (Wembley, Australia)
Peter Eastwood, PhD
University of Western Australia (Perth, Australia)
Hamid R. Sohrabi, PhD
Edith Cowan University (Perth, Australia)
Victor L. Villemagne, MD
Austin Health (Heidelberg, Australia)
YEAR AWARDED: 2018
GRANT DURATION: July 1, 2018 to June 30, 2020
DISEASE: Alzheimer's Disease
AWARD AMOUNT: $149,998
GRANT REFERENCE ID: A2018402F
AWARD TYPE: Postdoctoral Fellowship
AWARD REGION: International

Improving Sleep to Prevent Alzheimer's Disease

Summary
This study will explore the relationship between sleep, memory and thinking, and changes in the brain in Alzheimer’s disease (AD) by investigating whether improved sleep (better and longer) causes better memory and thinking, slower protein build up in the brain and slows the shrinking of the brain. The results will help us find a way to slow or stop this horrible disease. With sleep problems reported in 60 percent of adults over 65, my research will impact a significant proportion of the population.

Details
Alzheimer’s disease (AD) is a terrible illness which damages the brain of many older people, causing them to stop thinking clearly; to stop remembering important information about themselves, their family and their life; and to start behaving differently. These problems get so bad that daily tasks such as driving, reading, or finding the right words when speaking to someone become very difficult or impossible. We know that a particular protein builds up in the brain of a person with AD and that the brain becomes smaller, but we don’t know how to slow or stop the disease. Some scientists believe that sleep is important, but more work is needed to understand whether ‘how long’ and ‘how well’ someone usually sleeps changes how likely they are to get AD, or alters the speed at which the changes in the brain happen. My study will explore the relationship between sleep, memory and thinking, and changes in the brain, by investigating whether improved sleep (better and longer) causes improved memory and thinking, slower protein build up in the brain and slows the shrinking of the brain. Once complete, I hope that the results of my study will provide evidence for translation into a standard therapy for older adults at increased risk of AD due to sleep complaints.

About the Researcher
Stephanie was awarded a PhD in neuroscience from King’s College London in 2010. Continuing her work in the area of neurodegenerative diseases, in October 2010, Stephanie joined Professor Ralph Martins’ team in the Centre of Excellence for Alzheimer’s Disease Research and Care, based at Edith Cowan University (ECU) in Western Australia. Stephanie plays a lead role in the Clinical and Preventative Strategies group at ECU, working with researchers nationally and internationally to investigate lifestyle factors such as sleep, diet, and physical activity as potential preventative and therapeutic interventions for Alzheimer’s disease (AD). As evidenced by her publication track record, Stephanie employs multidisciplinary research approaches to identify lifestyle factors which impact upon cognitive decline and Alzheimer’s-related pathology. Stephanie also coordinates the West Australian arm of the internationally acclaimed Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing, and plays a leading research role in the Lifestyle stream of AIBL, working closely with other researchers in Western Australia and the eastern states of Australia, as well as internationally, to explore the relationship of sleep, diet and physical activity with healthy aging and AD.

Personal Story
Science was always my favourite subject at school, and it became obvious to me, at university, that I was particularly fascinated by neuroscience. A spell working in a lab setting as an intern 'sealed the deal' for me, and I knew that I wanted to pursue a career working in the field of neurodegenerative diseases. I was the recipient of a competitive Motor Neurone Disease Association-funded postgraduate research scholarship which enabled me to undertake a PhD in this field. Whilst my PhD focused on motor neurone disease, I was part of a lab where Alzheimer's disease (AD) was also a research focus, and soon after completion of my PhD, I side-stepped into the Alzheimer's research field. My passion for research has led me around the world to pursue the topics that I currently work on. I have driven research investigating lifestyle factors such as sleep, diet, and physical activity as potential preventative and therapeutic interventions for AD, which has led to multiple publications, and supervision of PhD student projects in lifestyle and biomarker research. All of which has directed me to the current project: Improving sleep to prevent AD. This project will allow me to integrate the multiple areas of my research and technical expertise, and provide a perfect synergy between my existing research expertise and my planned “next step” – specifically, the holistic integration of objective, well-supported lifestyle factors associated with AD, and biomarker research, which provides promise for clearer measurement of the effectiveness of future interventions aimed at altering these lifestyle risk factors. I am extremely grateful to the BrightFocus Foundation donors for their generous support, without which I would be unable to pursue this research project.

First published on: November 15, 2018



https://www.brightfocus.org/alzheimers-disease/grant/improving-sleep-prevent-alzheimers-disease



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist